T-lymphocytes subsets variation in breast cancer Egyptian patients

ABSTRACT

In this work, we investigate T-lymphocytes subsets in breast cancer patients among Egyptian populations to evaluate the immune response towards cancer and understanding their behavior towards tumor and normal cell growth before the influence of chemotheraputic agents under simple immune system response At first stage of disease. T cells are capable of in vivo expansion and provide protection for the immune effector cells re-populating the host. Survival of these cells and long-term memory development in patients with malignancy are necessary for improving clinical benefits of immunotherapy. By measuring CD4 and CD8 we recognized that no change in the helper T cells and Cytotoxic cells in these patients who were prepared to receive chemotherapeutic agents at the first stage and in the control group. T cells have been found with either deficient or normal functional activity in both groups these heterogeneous results greatly confuse the role played by CD4 T cells and CD8 responses. Immunological measures of white blood cell, lymphocyte, CD3+, CD4+, and CD8+ counts, 40 patients were divided into a control group [15] and patients group [25]. Total T-cell, helper T-cell and suppressor T-cell counts which [P<0.05], as well as control T-cell function [P < 0.05] when compared with normative data, were found some significant increase CD4 cells and CD4/CD8 ratio in cell count most of cases no changes to the total leukocyte lymphocyte CD3+and CD8+ count. Our study points out that immune response began to defend against tumor cells after a brief period of tumor stimulation but is still not sufficient to induce strong immune response. These data invite us to focus on period which immune system needs to respond which may help in deciding the possibility of immune therapy and determine when immune therapy can start